Last reviewed · How we verify

ROP+L-Dopa — Competitive Intelligence Brief

ROP+L-Dopa (ROP+L-Dopa) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist + Levodopa combination. Area: Neurology.

marketed Dopamine agonist + Levodopa combination Dopamine receptors (D2/D3); Dopamine pathway Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ROP+L-Dopa (ROP+L-Dopa) — GlaxoSmithKline. ROP+L-Dopa is a combination therapy that pairs ropinirole (a dopamine agonist) with levodopa to enhance dopaminergic signaling in the brain for Parkinson's disease management.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ROP+L-Dopa TARGET ROP+L-Dopa GlaxoSmithKline marketed Dopamine agonist + Levodopa combination Dopamine receptors (D2/D3); Dopamine pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist + Levodopa combination class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ROP+L-Dopa — Competitive Intelligence Brief. https://druglandscape.com/ci/rop-l-dopa. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: